Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy POSEIDON-DCM Trial

Overview of attention for article published in JACC, November 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 4 news outlets
twitter: 28 X users
patent: 1 patent

facebook: 3 Facebook pages
f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 294 Mendeley

So far, Altmetric has seen 5 news stories from 4 outlets.

Allogeneic stem cells show promise for treating nonischemic dilated cardiomyopathy

Pediatric News , 13 Jun 2026

The phase I/II trial undertook a head-to-head comparison of allogeneic and autologous bone marrow–derived mesenchymal stem…

Allogeneic stem cells show promise for treating nonischemic dilated cardiomyopathy

Pediatric News , 21 Feb 2025

NEW ORLEANS – Allogeneic stem cells appear to be a safe treatment option for nonischemic dilated cardiomyopathy and show…

Regenerative Therapy Makes Headway in HF ... in the Right Patients

MedPage Today, 02 Jul 2021

Cardiology > CHF Study of autologous skeletal cell-patch implantation in Japan Cell-patch therapy was safe and feasible for…

News story from Stat News on Friday 29 December 2017

Stat News, 29 Dec 2017

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.